Halozyme Therapeutics Inc... (HALO)
57.85
-0.44 (-0.75%)
At close: Feb 18, 2025, 3:59 PM
58.50
1.12%
After-hours: Feb 18, 2025, 07:48 PM EST
undefined% (undefined)
| Bid | 58.5 |
| Market Cap | 7.36B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 3.02 |
| PE Ratio (ttm) | 19.16 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 59.41 |
| Volume | 1,178,599 |
| Avg. Volume (20D) | 1,409,103 |
| Open | 58.84 |
| Previous Close | 58.29 |
| Day's Range | 57.61 - 58.90 |
| 52-Week Range | 35.50 - 65.53 |
| Beta | undefined |
About HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules a...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 16, 2004
Employees 373
Stock Exchange NASDAQ
Ticker Symbol HALO
Website https://www.halozyme.com
Analyst Forecast
According to 9 analyst ratings, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $60, which is an increase of 3.72% from the latest price.
Buy 55.56%
Hold 44.44%
Sell 0.00%
Next Earnings Release
Halozyme Therapeutics Inc. is scheduled to release its earnings on May 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.02%
Halozyme Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
2 months ago
+7.22%
Halozyme Therapeutics shares are trading higher after the company announced it withdrew plans to acquire Evotec.
